-
Luye Pharma and JD Health jointly hold bipolar disorder science lecture
Time of Update: 2021-07-12
"Unlike unipolar depression, patients with bipolar disorders also have a history of manic episodes, sometimes with high moods and sometimes low depressions, showing completely different states at different stages .
"Precision" treatment based on the patient's personal characteristics is the "artistic of clinical treatment" mentioned by Professor Zhang Yan .
-
WeDoctor submits prospectus, net loss exceeds 1.9 billion in 2020
Time of Update: 2021-07-12
According to Frost & Sullivan data quoted in the prospectus, based on the number of Internet hospitals by the end of 2020 and the number of digital diagnosis and treatment provided in 2019, WeDoctor is China’s largest digital medical service platform.
-
What is the basis for Gerry Pharmaceuticals to enter the oncology market?
Time of Update: 2021-07-12
In 2020, the European Medical Oncology Conference (ESMO) announced a researcher-initiated application of FASN inhibitor TVB-2640 (Gree code: ASC40) combined with bevacizumab for the treatment of glioblastoma II Phase clinical results showed that the objective response rate (ORR) of the program reached 65%, of which the complete response rate (CR) was 20%, the partial response rate (PR) was 45%; the 6-month PFS rate was 47%, which was significantly better than Historical control (BELOB 16%, P=0.
-
9 Tianjin hospitals jointly established a lysosomal storage disease collaboration group to promote standardized management of rare diseases
Time of Update: 2021-07-12
In order to further improve the rare disease management system in Tianjin and promote the early detection, early diagnosis and standardized treatment of lysosomal storage diseases, on March 27, 2021, the Tianjin Rare Disease Diagnosis and Treatment Network Lysosomal Storage Disorders Cooperation Group The establishment and academic seminar was successfully held in Tianjin Children's Hospital .
-
Henlius and Runxin Biotech reached an exclusive license cooperation on BRAF V600E inhibitor
Time of Update: 2021-07-12
It is expected to become a Best-in-Class BRAF V600E small molecule inhibitor, and the target product has the potential to compete with Henlius' EGFR , PD-1 target monoclonal antibody products have a synergistic effect, creating a better differentiated and innovative product portfolio in multiple cancer fields .
This cooperation will accelerate the clinical development and commercialization of our BRAF V600E inhibitor RX208 .
-
Takeda sells its US$670 million assets and injects US$500 million into BridGene
Time of Update: 2021-07-12
At the same time, as new technologies opened up new avenues for the development of small molecule drugs, Takeda decided to invest US$500 million in BridGene Biosciences, a drug research and development company .
-
Corning Jerry appoints Mr. Xu Weihao as Chief Financial Officer (CFO)
Time of Update: 2021-07-12
I hope to further promote the company's growth through my experience in the global market, biotechnology investment field and business development strategy .
-
Connoa Bio submitted the IPO prospectus of the Hong Kong Stock Exchange
Time of Update: 2021-07-11
The prospectus disclosed that Connoa's drug discovery and development work was jointly led by Chairman of the Board and Chief Executive Officer Chen Bo and Senior Vice President Wang Changyu .
-
Wolters Kluwer Medical Releases White Paper on "Five Driving Forces of Future Medical Care"
Time of Update: 2021-07-11
Recently, Wolters Kluwer Health, a global professional medical information service provider, released a series of white papers on the "Five Drivers of Future Medical Care", aimed at responding to the challenges of the new crown pneumonia epidemic to the healthcare system and meeting the medical reforms in the post-epidemic period .
-
Jiangxi Province's first vascular access center of excellence project launched
Time of Update: 2021-07-11
The vascular access center of excellence project aims to focus on the comprehensive capacity building of vascular access, promote the improvement of the overall level of medical care through concepts such as concept introduction, skill optimization, and talent training, and rely on medical consortium resources to promote the extended coverage of the vascular access professional service network for the majority of patients Provide professional, convenient, secure and caring services .
-
Junshi Bio-Treprimumab injection is approved for the treatment of urothelial cancer
Time of Update: 2021-07-11
He has been treated for unresectable or metastatic melanoma that has failed systemic treatment in the past, and has been recommended by the Chinese Society of Clinical Oncology (CSCO) Melanoma Diagnosis and Treatment Guidelines in 2019 and 2020 .
-
Essen Medical joins Sorrento Medical, a listed company in the U.S.
Time of Update: 2021-07-11
In addition, Aisen focuses on the research and development of small molecule original innovative drugs.
-
Shengmei Biologics Series B financing, liquid tumor biopsy achieved a breakthrough in the field of lung cancer?
Time of Update: 2021-07-11
CAC testing is to detect the number of circulating chromosomal abnormal cells (CAC) in the blood of patients with lung nodules, indicating the high or low risk of early lung cancer .
-
An electronic prescription center will be established in the Boao Medical Pioneer Zone, and online prescription drugs will be sold in Hainan?
Time of Update: 2021-07-11
On April 8, the National Development and Reform Commission held a press conference and introduced that the electronic prescription center will be established in Lecheng Pioneer District in response to the current difficulties in the openness of online prescription drug prescription mutual recognition, patient privacy protection, and medical insurance settlement.
-
Zhaoke Ophthalmology, which was split by Li's major pharmaceutical company, passed the Hong Kong Stock Exchange hearing and will lose 727 million yuan in 2020
Time of Update: 2021-07-11
According to the Zhaoke Ophthalmology Prospectus, there are currently 23 drug candidates in the pipeline of Zhaoke Ophthalmology's research drugs, including 11 innovative drugs and 12 generic drugs, covering most major ophthalmic diseases and symptoms that affect the front and back of the eye .
-
Dongfang Qiyin "Guardian Blue Boy": Your attention may be a real guardian
Time of Update: 2021-07-11
Oriental Qiyin launched the "Guardian Blue Child" Autism Day theme activity, guided by China Population Welfare Foundation and Shenzhen Comprehensive Service Center for the Disabled , Starlight Volunteers Association, Zhongzhou Future Laboratory, EqualOcean, Yilin Health Education Exhibition Center, Weimai, Fullerton Medical Group, STAR AUTISM SUPPORT, and Yakult are the public welfare cooperation units of this event.
-
Qiming Medical Announces 2020 Annual Results, Continues to Lead Market Growth
Time of Update: 2021-07-11
Although the number of terminal surgeries in hospitals fell in the first half of 2020 due to the impact of the new coronary pneumonia epidemic in the first half of 2020, after the epidemic was controlled in the second half of the year, the growth rate of VenusA-Valve, the main product of Qiming Medical, for transcatheter aortic valve replacement (TAVR), recovered significantly .
-
Tengshengbo Pharmaceutical submitted the HKEx IPO prospectus to complete US$150 million in Series C financing
Time of Update: 2021-07-11
The prospectus disclosed that Tengsheng Bo Pharmaceutical was founded in December 2017 and is a biotechnology company that focuses on public health diseases represented by infectious diseases .
-
Yasheng Pharmaceutical releases 2020 full-year results, the commercialization of core products is imminent
Time of Update: 2021-07-11
The company's first NDA was included in the priority review, and commercialization was fully launched As the core product of Ascent Pharmaceuticals, the third-generation BCR-ABL inhibitor HQP1351 ushered in a number of major milestones during the reporting period .
-
The first domestic phase III clinical trial of a new treatment for cognitive impairment in schizophrenia was approved
Time of Update: 2021-07-11
Recently, Boehringer Ingelheim's central nervous pipeline drug BI425809 for the treatment of cognitive impairment (CIAS) in patients with schizophrenia was approved by the Drug Evaluation Center of the National Medical Products Administration in a phase III clinical trial.
